We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Accelerating Progress in Preventing Resistance to Anticancer Drugs

News   Aug 05, 2020 | Original story from the Huntsman Cancer Institute

 
Accelerating Progress in Preventing Resistance to Anticancer Drugs

Scientists at Huntsman Cancer Institute at the University of Utah report today the development of new models to study molecular characteristics of tumors of the lung and pancreas that are driven by mutations in a gene named NTRK1. The findings were published today in the journal Cell Reports. Credit: Huntsman Cancer Institute

 
 
Advertisement
 

RELATED ARTICLES

How the Loss of a Single Protein Leads to a Relentless Neuromuscular Disease

News

A new study has laid out the steps that connect the neuromuscular disorder spinal muscular atrophy (SMA) to the mutations in the gene SMN1 that cause the condition. The research may explain how the mutations affect motor neurons and points the way to a better understanding of SMA.

READ MORE

KRAS Inhibitor Sotorasib Achieves Durable Clinical Benefit in Early Trial

News

In a Phase I clinical trial for patients with advanced solid cancers marked by KRAS G12C mutations, the KRASG12C inhibitor sotorasib (AMG 510) resulted in manageable toxicities and durable clinical benefit.

READ MORE

Could Psoriatic Arthritis Be Activated by the Same Receptor in Different Patients?

News

A new study has revealed psoriatic arthritis may be activated by the same trigger in different patients. Researchers identified high levels of a specific receptor in immune cells, giving promising evidence of a single cause for the disease.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Cancer Research Drug Discovery Genomics Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE